Skip to main content

Table 1 Selected small cell lung cancer trials

From: Immunotherapy in extensive small cell lung cancer

Name of trial

Phase

Therapy

mOS

mPFS

ORR (%)

Ref

CheckMate 032 (relapsed extensive stage)

1/2

Nivolumab 3 mg/kg

NR

NR

10

[7]

Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg

NR

NR

33

Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg

NR

NR

23

Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg

NR

NR

19

IMpower 133 (treatment naive extensive stage)

3

Carboplatin/Etoposide 4 cycles

10

4.3

 

[11]

Carboplatin/Etoposide/Atezolizumab 4 cycles—Atezolizumab maintenance

12

5.2

 

Name of trial

Ongoing trials

Phase

Therapy

Primary endpoints

Secondary endpoints

Ref

 

CheckMate 331 (relapsed)

3

Nivolumab

OS

PFS, ORR

[12]

 

Topotecan

CheckMate 451 (maintenance after response to platinum doublet

3

Nivolumab

OS

PFS

[13]

 

Nivolumab + Ipilimumab

Placebo

KeyNote 158 (relapsed/refractory)

2

Keytruda

ORR

OS, PFS, DOR

[14]

 

KeyNote 028 (extensive stage)

1

Keytruda

ORR

OS, PFS, DOR

[15]

 
  1. mOS median overall survival, mPFS median progression free survival, ORR objective response rate, Ref reference, NR not reached, OS overall survival, PFS progression free survival, DOR duration of response